[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627545":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":18,"locations":24,"responsibleParty":38,"collaborators":10,"id":42,"slug":43,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":10,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Elazığ Mental Health and Diseases Hospital","OTHER_GOV",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Methamphetamine Use Disorder",null,"Adult participants (18-65 years) diagnosed with Methamphetamine Use Disorder according to DSM-5-TR criteria. Participants were\u002Fwill be evaluated at hospital admission (baseline). No intervention was\u002Fwill be assigned by the study protocol. Blood samples were\u002Fwill be collected for measurement of serum LRFN5 and OLFM4 levels and complete blood count parameters. No psychometric scales were\u002Fwill be administered to this group. Sociodemographic and clinical data were\u002Fwill be recorded for all participants.",{"label":13,"type":10,"description":14,"interventionNames":10},"Methamphetamine-Induced Psychotic Disorder","Adult participants (18-65 years) diagnosed with Methamphetamine-Induced Psychotic Disorder according to DSM-5-TR criteria. Participants were\u002Fwill be evaluated at hospital admission (baseline). No intervention was\u002Fwill be assigned by the study protocol. Blood samples were\u002Fwill be collected for measurement of serum LRFN5 and OLFM4 levels and complete blood count parameters. Psychotic symptom severity was\u002Fwill be assessed using the Positive and Negative Syndrome Scale (PANSS). Insight Assessment Scale was\u002Fwill be used to measure the insight level. Sociodemographic and clinical data were\u002Fwill be recorded for all participants.",{"label":16,"type":10,"description":17,"interventionNames":10},"Healthy Control","Healthy control adult participants (18-65 years) without any current or past psychiatric disorder. No intervention was administered as part of the research protocol. Participants underwent a baseline clinical evaluation and provided a single blood sample for measurement of serum α-N-acetylgalactosaminidase levels and complete blood count inflammatory markers. Sociodemographic and clinical data were recorded for all participants. As of January 6, 2026, the recruitment of healthy control participants has been completed.",[19],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},"Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist","CONTACT","+905382207558","mhorum@hotmail.com",[25],{"facility":5,"status":26,"city":27,"state":27,"zip":28,"country":29,"countryCode":10,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"RECRUITING","Elâzığ","23200","Turkey (Türkiye)",{"type":31,"coordinates":32},"Point",[33,34],39.22321,38.67431,{"lat":34,"lon":33},[37],{"name":20,"role":21,"phone":22,"phoneExt":10,"email":23},{"type":39,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Mehmet Hamdi ÖRÜM","Associate Professor Mehmet Hamdi Örüm, MD, Psychiatrist","100627545","lrfn5-and-olfm4-in-methamphetamine-induced-psychosis-100627545",false,"NCT07450027","LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis","Serum LRFN5 and OLFM4 Levels in Methamphetamine Use Disorder and Methamphetamine-Induced Psychotic Disorder: A Cross-Sectional Case-Control Study","1. For Methamphetamine Use Disorder (MUD) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of MUD according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine Use Disorder (MUD) Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MUD\n   * Alcohol use disorder\n2. For Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n   \\*Inclusion Criteria:\n   * Diagnosis of MP according to DSM-5-TR\n   * Medication-free for at least one month prior to admission\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Methamphetamine-Induced Psychotic Disorder (MP) Group:\n\n   \\*Exclusion Criteria:\n   * Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than MP\n   * Alcohol use disorder\n3. For Healthy Control Group:\n\n   \\*Inclusion Criteria:\n   * No psychiatric diagnosis\n   * No systemic or immunological illness\n   * Medication-free for at least one month\n   * Age ≥ 18 years and \\\u003C65 years\n   * Provided informed consent\n\n   For Healthy Control Group:\n\n   \\*Exclusion Criteria:\n\n   • Hypertension\n   * Diabetes mellitus\n   * Chronic kidney disease\n   * Rheumatoid arthritis\n   * Systemic lupus erythematosus\n   * Cardiac illness\n   * Severe neurological disorders\n   * Immunological or systemic illness\n   * Primary psychiatric disorders other than schizophrenia\n   * Alcohol\u002Fdrug\u002Fsubstance use",true,"MALE","18 Years","49 Years",{"count":54,"type":55},120,"ESTIMATED","OBSERVATIONAL","This cross-sectional observational case-control study aimed to examined serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) levels in methamphetamine use disorder (MUD), methamphetamine-induced psychotic disorder (MP), and healthy control (HC) groups. The study also aimed to assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Insight Assessment Scale (IAS) and Positive and Negative Syndrome Scale (PANSS) scores.",[9,59],"Methamphetamine-induced Psychosis",[61,62,63,64,65,66],"LRFN5","OLFM4","Methamphetamine","Psychotic Disorder","Methamphetamine Psychosis","Psychostimulants","2026-02-27",{"date":69,"type":70},"2026-03-04","ACTUAL",{"date":72,"type":70},"2025-09-01",{"date":74,"type":55},"2026-04-01",{"name":5,"class":6},1]